Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
2024年1月18日 - 6:01AM
ビジネスワイヤ(英語)
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology
company focused on discovering and developing potential
best-in-class medicines for serious and rare diseases, today
announced that it has commenced an underwritten public offering of
shares of its common stock and Series B preferred stock. All of the
securities to be sold in the underwritten public offering are being
offered by Viridian. In addition, Viridian intends to grant the
underwriters a 30-day option to purchase additional shares of its
common stock. Each share of Series B preferred stock will be
convertible into 66.67 shares of common stock at the election of
the holder, subject to beneficial ownership conversion limits
applicable to the Series B preferred stock.
Viridian intends to use the proceeds from the proposed
underwritten public offering of its shares of common stock and
Series B preferred stock, together with its cash, cash equivalents
and short-term investments, to further its clinical development
programs, as well as for working capital and general corporate
purposes.
Jefferies and Leerink Partners are acting as joint lead
book-running managers for the proposed offering.
A registration statement relating to these securities has been
filed with the Securities and Exchange Commission (SEC) and became
effective on September 9, 2022. A preliminary prospectus supplement
and accompanying base prospectus relating to and describing the
terms of the offering will be filed with the SEC. The securities
described above have not been qualified under any state blue sky
laws. This press release shall not constitute an offer to sell or
the solicitation of an offer to buy these securities, nor shall
there be any sale of these securities in any state or other
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to the registration or qualification under the
securities laws of any such state or other jurisdiction. The
offering can be made only by means of a prospectus, copies of which
may be obtained at the SEC’s website at www.sec.gov, or by request
to Jefferies LLC (Attention: Equity Syndicate Prospectus
Department, 520 Madison Avenue, New York, New York 10022;
telephone: 877-821-7388; email:
Prospectus_Department@Jefferies.com) or Leerink Partners LLC,
Attention: Syndicate Department, 53 State Street, 40th Floor,
Boston, MA 02109, by telephone at (800) 808-7525, ext. 6105, or by
email at syndicate@leerink.com.
About Viridian Therapeutics, Inc.
Viridian is a biopharmaceutical company focused on engineering
and developing potential best-in-class medicines for patients with
serious and rare diseases. Viridian’s expertise in antibody
discovery and engineering enables it to develop differentiated
therapeutic candidates for previously validated drug targets in
commercially established disease areas.
Viridian is advancing multiple candidates in the clinic for the
treatment of patients with thyroid eye disease (TED). The company
is conducting two global Phase 3 clinical trials (THRIVE and
THRIVE-2) to evaluate the safety and efficacy of VRDN-001 in
patients with active and chronic TED. Viridian’s goal is to advance
VRDN-001 as a best-in-class IV therapy followed by VRDN-003 as a
first- and best-in-class subcutaneous therapy for the treatment of
TED. In addition to its TED portfolio, Viridian is advancing a
novel portfolio of neonatal Fc receptor (FcRn) inhibitors, VRDN-006
and VRDN-008, which has the potential to be developed in multiple
autoimmune diseases.
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. These statements may be identified by the use of words such
as, but not limited to, “anticipate,” “believe,” “continue,”
“could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,”
“potential,” “predict,” “project,” “should,” “target,” “will,” or
“would” or other similar terms or expressions that concern the
company’s expectations, plans and intentions. Forward-looking
statements include, without limitation, statements regarding the
proposed underwritten public offering and the company’s
expectations with respect to the use of the net proceeds from the
proposed underwritten public offering. Forward-looking statements
are neither historical facts nor assurances of future performance.
Instead, they are based on the company’s current beliefs,
expectations and assumptions. New risks and uncertainties may
emerge from time to time, and it is not possible to predict all
risks and uncertainties. No representations or warranties
(expressed or implied) are made about the accuracy of any such
forward-looking statements. Such forward-looking statements are
subject to a number of material risks and uncertainties including
but not limited to: market conditions that may affect the timing,
terms or conditions of the proposed underwritten public offering;
the company’s successful completion of the proposed underwritten
public offering; the satisfaction of customary closing conditions
related to the proposed underwritten public offering; and other
risks and uncertainties identified in the company’s filings with
the SEC, including those risks set forth under the caption “Risk
Factors” in the company’s Quarterly Report on Form 10-Q filed with
the SEC on November 13, 2023 and other subsequent disclosure
documents filed with the SEC. Any forward-looking statement speaks
only as of the date on which it was made. Neither the company, nor
its affiliates, advisors or representatives, undertake any
obligation to publicly update or revise any forward-looking
statement, whether as a result of new information, future events or
otherwise, except as required by law. These forward-looking
statements should not be relied upon as representing the company’s
views as of any date subsequent to the date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240115733377/en/
Investor & Media Contact: Louisa Stone, 617-272-4604
Manager, Investor Relations IR@viridiantherapeutics.com
Viridian Therapeutics (NASDAQ:VRDN)
過去 株価チャート
から 4 2024 まで 5 2024
Viridian Therapeutics (NASDAQ:VRDN)
過去 株価チャート
から 5 2023 まで 5 2024